Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non‐small‐cell lung cancer

Patrick Micke(Uppsala University), Özlem Türeci(MerLion Pharma (Germany))
International Journal of Cancer
March 19, 2014
10.1002/ijc.28857
Cited by 132

Related Papers

mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
|Nature|2020|2k
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
|Nature|2021|828